A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerAlberto Chiappori, M. S. Berger, Johnetta Blakely et al.|British Journal of Cancer|2012Cited by 51
A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)Alberto Chiappori, M. S. Berger, Marshall T. Schreeder et al.|Journal of Clinical Oncology|2009Cited by 11